Overview

Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia

Status:
Unknown status
Trial end date:
2019-02-28
Target enrollment:
0
Participant gender:
Female
Summary
This study evaluates Buxue Yimu Pills,Ferrous Sulfate and the addition of Buxue Yimu Pills to Ferrous Sulfate in the treatment of Iron-Deficiency Anemia in adults women. One third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Ferrous Sulfate,and the another third will receive Buxue Yimu Pills and Ferrous Sulfate in combination.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Iron
Criteria
Inclusion Criteria:

- Subject is a female between the age of 18 and 50.

- Subject suffers from mild to moderate anemia with a hemoglobin between 80g/L and 110
g/L.

- Subject has definite gynecological etiological factors of iron deficiency

- Subject provides written informed consent.

Exclusion Criteria:

- Subject underwent chronic digestive tract inflammation,uncontrolled digestive or
urinary system bleeding.

- Subject has other complications in addition to gynecological diseases leading to iron
deficiency,such as hemorrhagic diseases of hematologic system,parasitic diseases like
ancylostomiasis,chronic intravascular hemolysis,mechanical hemolysis like prosthetic
valve,renal dysfunction and hemodialysis.

- Subject is pregnant or lactating.

- Subject has a severe systemic disease, such as cardiovascular system

- Subject has a history of malignancy or radiotherapy.

- Subject has undergone any Iron deficiency anemia treatment including Iron supplements
or blood transfusion within 1month prior to randomization.

- Subject has mental disorder incapable of elementary cooperations.

- Subject has participated in other clinical researches of medicine within 1month prior
to randomization.